Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
IBRANCE 75 mg hard capsules - Summary of Product Characteristics (SmPC) - (emc)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind ...
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | Breast Cancer Research
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Sustained OS on Palbociclib in MBC | PPT
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
Frontiers | Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer - Yi Li, Wei Li, Chengcheng Gong, Yabin Zheng, Quchang Ouyang,
Ibrance: Package Insert - Drugs.com
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | Breast Cancer Research
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 -
Journal of Breast Disease
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study - Ha - 2022 -
IBRANCE® capsules (palbociclib) Clinical Studies | Pfizer Medical Information - US
![ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/202206/13831_14395_1052.jpg "ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR")
ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
A) Progression-free survival (PFS) curves by lines receiving... | Download Scientific Diagram
Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2− Advanced/Metastatic Breast Cancer | In Vivo
Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole | Breast Cancer
No Clear Survival Benefit for Fulvestrant Versus Letrozole in Combination With Palbociclib for Endocrine-Sensitive Metastatic Breast Cancer
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
A) Kaplan–Meier curve of progression-free survival in patients who... | Download Scientific Diagram
